Jefferies Starts Gemphire Therapeutics (GEMP) at Buy
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Jefferies initiates coverage on Gemphire Therapeutics (NASDAQ: GEMP) with a Buy rating and a price target of $15.00.
Analyst Matthew Andrews commented, "Initiating with a Buy Rating and $15 price target. Gemcabene is being developed to address the large, evolving global dyslipidemia market. If gemcabene’s profile and Ph. II(b)/III data replicate Pfizer’s Ph. I/II(a) data, we believe it can ultimately become a broadly-adopted 2nd Line agent used with statins. We estimate 2036 global-adjusted royalties to GEMP of $385M."
Shares of Gemphire Therapeutics closed at $10.15 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies Reiterates Buy on PPG Industries (PPG) - PT to $113
- Credit Suisse Downgrades Time Warner (TWX) to Neutral Following Takeover
- Wedbush Raises Price Target on Citizens Financial Group (CFG) Following 3Q EPS Beat
Create E-mail Alert Related CategoriesAnalyst Comments, New Coverage
Related EntitiesJefferies & Co
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!